Bcwm LLC Invests $6.36 Million in Bristol Myers Squibb Company $BMY

Key Points

• Bcwm LLC acquired 110,424 Bristol Myers Squibb shares worth approximately $6.36 million in the second quarter, making BMY 1.9% of its portfolio. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly EPS of $2.04, exceeding estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company issued fiscal 2026 EPS guidance of $6.75–$7.00.
• BMY shares opened at $67.68, near their 52-week high, and the company pays a quarterly dividend of $0.63, representing a 3.7% annualized yield. Analysts hold a consensus “Moderate Buy” rating with an average price target of $66.06.

Bcwm LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 110,424 shares of the biopharmaceutical company's stock, valued at approximately $6,363,000. Bristol Myers Squibb comprises about 1.9% of Bcwm LLC's holdings, making the stock its 27th biggest holding.

Several other large investors also recently added to or reduced their stakes in BMY. BlackRock Inc. raised its position in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp grew its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC increased its stake in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Norges Bank bought a new position in Bristol Myers Squibb in the 4th quarter worth $1,947,272,000. Finally, AQR Capital Management LLC raised its holdings in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 0.4%

Shares of BMY stock opened at $67.68 on Thursday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $138.25 billion, a PE ratio of 14.91, a PEG ratio of 0.18 and a beta of 0.22. The stock has a fifty day simple moving average of $61.25 and a two-hundred day simple moving average of $59.60.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.05% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on BMY shares. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 27th. Royal Bank Of Canada raised their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Citigroup reaffirmed a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Weiss Ratings upgraded Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Finally, Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.